Get the Stockscreener App
3.00
0.00%
0.00
Pre-market:
3.01
0.010
+0.33%
Macrogenics Inc stock is traded at $3.00, with a volume of 576.47K.
It is up +0.00% in the last 24 hours and down -5.66% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
See More
Previous Close:
$3.00
Open:
$2.99
24h Volume:
576.47K
Relative Volume:
1.03
Market Cap:
$188.29M
Revenue:
$56.91M
Net Income/Loss:
$-9.06M
P/E Ratio:
-18.75
EPS:
-0.16
Net Cash Flow:
$-79.97M
1W Performance:
-1.32%
1M Performance:
-5.66%
6M Performance:
-39.02%
1Y Performance:
-75.00%
1-Day Range:
$2.91
$3.03
1-Week Range:
$2.91
$3.22
52-Week Range:
$2.91
$21.88
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.00 | 188.29M | 56.91M | -9.06M | -79.97M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
Barclays PLC Acquires 48,639 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Macrogenics Stock Hits 52-Week Low at $2.95 Amid Market Challenges - MSN
Macrogenics Stock Hits 52-Week Low at $2.95 Amid Market Challenges By Investing.com - Investing.com South Africa
JMP Securities Downgrades MacroGenics (MGNX) - MSN
Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential - GlobeNewswire Inc.
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Average PT from Brokerages - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Analysts - Defense World
Geode Capital Management LLC Sells 8,363 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to - GuruFocus.com
Barclays PLC Has $325,000 Stake in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus.com
Stifel Financial Corp Purchases 6,578 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
State Street Corp Has $4.70 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Shares Acquired by Fmr LLC - Defense World
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Victoria Advocate
Faruqi & Faruqi Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - The Eastern Progress Online
MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Analysts Set MacroGenics, Inc. (NASDAQ:MGNX) PT at $7.63 - MarketBeat
MacroGenics' SWOT analysis: oncology firm faces pipeline challenges, stock outlook mixed - Investing.com Australia
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics - The Eastern Progress Online
Pharma Co. Brass Face Investor Suit Over Drug Trial Probe - Law360
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc.MGNX - The Eastern Progress Online
MacroGenics, Inc. Class Action: The Gross Law Firm Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - The Eastern Progress Online
Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - The Eastern Progress Online
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics - The Eastern Progress Online
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
MacroGenics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit - The Eastern Progress Online
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - The Eastern Progress Online
Jacobs Levy Equity Management Inc. Purchases 147,438 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):